11 Jun 2024 • Imetelstat has been approved by the FDA for adults with low-to intermediate-risk myelodysplastic syndromes (MDS) and transfusion-dependent anemia who have not responded or are ineligible for other treatments.

• The approval was based on a clinical trial in which patients received either imetelstat or a placebo. The trial showed that the imetelstat group had a higher rate of transfusion independence compared to the placebo group.

• Some common side effects of imetelstat include decreased platelets, white blood cells, and neutrophils, as well as increased liver enzymes and fatigue. The recommended dosage is 7.1 mg/kg administered via IV infusion every 4 weeks.

Source: FDA | Read full story